Nitroxide Spin-Labeled Amyloid Imaging Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Alzheimer's disease, particularly through MRI, face challenges due to reliance on endogenous iron for amyloid plaque detection, which is unreliable and limited by iron-poor regions in the brain, and existing contrast agents like Gd(III) have limitations such as kidney or liver contraindications and inflammatory responses.
Innovation Solution
Development of nitroxide spin-labeled compounds that bind to amyloid beta peptides, allowing for effective imaging through magnetic resonance imaging (MRI) without relying on endogenous iron and minimizing adverse reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MRI relies on endogenous iron for amyloid plaque detection, then imaging can be performed without exogenous contrast agents, but the detection reliability is poor and limited by iron-poor regions in the brain
Solution Approach 1:
The patent extracts the contrast-generating function from endogenous iron and transfers it to exogenous nitroxide spin-labeled compounds. These compounds specifically bind to amyloid beta peptides and generate detectable MRI signals through their nitroxide groups, eliminating dependence on variable endogenous iron levels in different brain regions.
Solution Approach 2:
The patent changes the contrast mechanism parameter from iron-dependent T2* relaxation to nitroxide-based relaxation enhancement. The nitroxide spin labels provide consistent contrast through their unpaired electrons, which interact with water protons to enhance relaxation rates, providing reliable detection regardless of regional iron content.
2Measurement precision
If Gd(III) contrast agents are used for amyloid imaging, then imaging sensitivity is improved, but contraindications arise in patients with kidney or liver disease and inflammatory responses occur
Solution Approach 1:
The patent employs nitroxide spin labels that are metabolically stable but ultimately degraded to harmless products. The nitroxide group provides the necessary contrast function temporarily during imaging, then undergoes natural metabolic pathways without accumulating in a toxic form, making it safer for patients with compromised organ function.
Solution Approach 2:
The patent changes the contrast agent chemistry from gadolinium-based chelates to organic nitroxide compounds. This substitution eliminates the nephrotoxicity and inflammatory issues associated with Gd(III) while maintaining adequate contrast through the nitroxide spin's interaction with surrounding water protons, providing a safer profile for vulnerable patient populations.
3Measurement precision
If iron-rich amyloid plaques are targeted for MRI contrast, then negative contrast is generated in iron-rich regions, but iron-poor amyloid depositions produce no signal
Solution Approach 1:
The patent creates a universal contrast mechanism that works for all amyloid beta depositions regardless of iron content. The nitroxide spin-labeled compounds bind directly to amyloid beta peptides through their targeting moiety, and the nitroxide group provides consistent contrast enhancement, making the detection method universally applicable to both iron-rich and iron-poor plaques.
Solution Approach 2:
The patent introduces nitroxide spin-labeled compounds as intermediary agents that mediate between the amyloid beta peptides and the MRI detection system. These compounds specifically recognize and bind to amyloid beta, transferring the detection capability to regions regardless of their iron content, thereby serving as a universal mediator for amyloid visualization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nitroxide spin-labeled compounds provide specific and safe contrast for amyloid imaging, enabling early detection of Alzheimer's disease with improved resolution and reduced side effects, as demonstrated by significant signal suppression and specificity in MRI and EPR analyses.
Implementation Method 1
allowing for effective imaging through magnetic resonance imaging (MRI)
Implementation Method 2
nitroxide spin-labeled compounds that bind to amyloid beta peptides
Implementation Method 3
detecting the compound bound to the amyloid, thereby imaging the amyloid
Data Source
Figure 1~3
Figure 4
Figure 5
AI summary
The present invention provides methods of using nitroxide spin-labeled amyloid beta-binding compounds to image amyloid. The present invention also provides nitroxide spin-labeled amyloid beta-binding compounds